PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31992334-9	2020	Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels.	Sorafenib	64-73	CD44 molecule (Indian blood group)	Homo sapiens	13-17	
31992334-9	2020	Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels.	Sorafenib	79-88	CD44 molecule (Indian blood group)	Homo sapiens	13-17	
31992334-9	2020	Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels.	Sorafenib	79-88	CD44 molecule (Indian blood group)	Homo sapiens	99-103	
31992334-11	2020	In addition, there was a highly synergistic effect in vitro and in vivo on the suppression of cell viability and malignant properties when sorafenib and GANT61 were added to CD44-positive HCC PDOs and cell lines, respectively.	Sorafenib	139-148	CD44 molecule (Indian blood group)	Homo sapiens	174-178	
31992334-12	2020	Furthermore, the upregulation of CD44 and Hedgehog signaling induced by sorafenib was reversed by GANT61.	Sorafenib	72-81	CD44 molecule (Indian blood group)	Homo sapiens	33-37	
31992334-13	2020	CONCLUSIONS: GANT61 significantly suppressed Hedgehog signaling to reverse sorafenib resistance in CD44-positive HCC.	Sorafenib	75-84	CD44 molecule (Indian blood group)	Homo sapiens	99-103	
31992334-14	2020	The combination of sorafenib and Hedgehog signaling inhibitors might be effective in HCC patients with high CD44 levels as a personalized-medicine approach.	Sorafenib	19-28	CD44 molecule (Indian blood group)	Homo sapiens	108-112